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Résumé 
Contexte: La régurgitation mitrale (RM) est une maladie valvulaire nécessitant une 
intervention dans les cas les plus grave. Une réparation percutanée de la valve mitrale 
avec le dispositif MitraClip est un traitement sécuritaire et efficace pour les patients à 
haut risque chirurgical. Nous voulons évaluer les résultats cliniques et l'impact 
économique de cette thérapie par rapport à la gestion médicale des patients en 
insuffisance cardiaque avec insuffisance mitrale symptomatique. 
Méthodes: L'étude a été composée de deux phases; une étude d'observation de patients 
souffrant d'insuffisance cardiaque et de régurgitation mitrale traitée avec une thérapie 
médicale ou le MitraClip, et un modèle économique. Les résultats de l'étude 
observationnelle ont été utilisés pour estimer les paramètres du modèle de décision, qui a 
estimé les coûts et les avantages d'une cohorte hypothétique de patients atteints 
d'insuffisance cardiaque et insuffisance mitrale sévère traitée avec soit un traitement 
médical standard ou MitraClip. 
Résultats: La cohorte de patients traités avec le système MitraClip était appariée par 
score de propension à une population de patients atteints d'insuffisance cardiaque, et leurs 
résultats ont été comparés. Avec un suivi moyen de 22 mois, la mortalité était de 21% 
dans la cohorte MitraClip et de 42% dans la cohorte de gestion médicale (p = 0,007). Le 
modèle de décision a démontré que MitraClip augmente l'espérance de vie de 1,87 à 3,60 
années et des années de vie pondérées par la qualité (QALY) de 1,13 à 2,76 ans. Le coût 
marginal était 52.500 $ dollars canadiens, correspondant à un rapport coût-efficacité 
différentiel (RCED) de 32,300.00 $ par QALY gagné. Les résultats étaient sensibles à 
l'avantage de survie. 
Conclusion: Dans cette cohorte de patients atteints d'insuffisance cardiaque 
symptomatique et d insuffisance mitrale significative, la thérapie avec le MitraClip est 
associée à une survie supérieure et est rentable par rapport au traitement médical. 
Mots-clés : insuffisance mitrale, insuffisance cardiaque, analyse de couts, réparation de la 
valve mitrale 
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Abstract 
Background:  Mitral regurgitation (MR) is a common valvular heart disorder requiring 
intervention once it becomes severe. Transcatheter mitral valve leaflet repair with the 
MitraClip device is a safe and effective therapy for selected patients denied surgery.  We 
sought to evaluate the clinical outcomes and economic impact of this therapy compared 
to medical management in heart failure patients with symptomatic MR. 
 
Methods:  The study was comprised of two phases; an observational study of patients 
with heart failure and MR treated with either medical therapy or the MitraClip, and an 
economic model. Results of the observational study were used to estimate parameters for 
the decision model, which estimated costs, and benefits in a hypothetical cohort of 
patients with heart failure and moderate to severe MR treated with either standard 
medical therapy or MitraClip.  
 
Results:  The cohort of patients treated with the MitraClip was propensity matched to a 
population of heart failure patients, and their outcomes compared. At a mean follow up of 
22 months, all-cause mortality was 21% in the MitraClip cohort and 42% in the medical 
management cohort (p=0.007).  The decision model demonstrated that MitraClip 
increased life expectancy from 1.87 to 3.60 years and quality-adjusted life years (QALY) 
from 1.13 to 2.76 years. The incremental cost was $52,500 Canadian dollars, 
corresponding to an incremental cost-effectiveness ratio (ICER) of $32,300.00 per QALY 
gained.  Results were sensitive to the survival benefit. 
 
Conclusion: In this cohort of heart failure patients with symptomatic moderate-severe 
MR, therapy with the MitraClip was associated with superior survival and is cost-
effective compared to medical therapy. 
 
Keywords: mitral regurgitation, heart failure, transcatheter mitral repair, cost-
effectiveness 
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Introduction 
Mitral regurgitation (MR) is one of the most common valvular heart disorders, with an 
estimated prevalence in the US of ~1.7%, increasing with age to ~9.3% in those >75 years in a 
population study performed in New York State(1). In the 2001 EuroHeart Survey, MR was 
second in frequency only to aortic stenosis with a prevalence of 24.8% in patients with 
valvular heart disease(2).  The standard of care for severe symptomatic MR is surgical mitral 
valve repair or replacement according to published guidelines(3, 4).  Nevertheless, a 
significant number of patients do not receive intervention due to severe comorbidities and high 
surgical risk and are treated medically, particularly those with left ventricular dysfunction, 
symptoms of heart failure (HF) and secondary or functional MR (FMR)(5).  In such patients, 
the presence of significant MR has been shown to independently predict mortality and 
hospitalizations for HF(6). HF is costly for the healthcare system; exceeding $40 billion 
dollars in 2012 in the US(7) therefore effective therapies may provide significant clinical and 
economic benefits. 
 Transcatheter mitral valve repair using the MitraClip (Abbott Vascular, Menlo Park, 
CA) has been commercially available in Europe since 2008 and in Canada since 2010.  Such 
therapy involves the transcatheter placement of a metal clip on the leaflets of the mitral valve 
at the site of valvular regurgitation thereby reducing MR and resulting in a double-orifice 
mitral valve(8).  Evaluation of this technology in surgical candidates has established superior 
safety, albeit with less efficacy when compared with surgical repair or replacement(9).   
 Current clinical experience with the MitraClip has focused on high-risk patients rather 
than surgical candidates, and in particular those with HF and FMR. In the post-approval 
ACCESS-EU registry, the MitraClip was implanted in 567 patients with a clip implant rate of 
99.6% and MR reduction in 91% of patients, with no procedural mortality(10). Through 12-
month follow-up, NYHA class and 6-minute walk distance were substantially improved. 
Numerous other centers in Europe have published their clinical experience of MitraClip in 
FMR but as yet there has not been a comparison to patients treated medically(11). 
Large-scale randomized controlled trials are currently underway in HF patients to 
evaluate the efficacy of this intervention compared to medical therapy.  We sought to compare 
a cohort of patients with HF and FMR treated with MitraClip to a cohort of medically 
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managed patients at our institution.  The economic burden of HF on the healthcare system, 
lack of effective interventional options for many patients, and the substantial up-front costs of 
such technology, are the basis of this evaluation of the cost-effectiveness of the MitraClip 
based on data from patients treated with this device at our institution. 
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Background 
Mitral Regurgitation 
Mitral regurgitation (MR) is one of the most common valvular heart disorders, with an 
estimated prevalence in the US of ~1.7%, increasing with age to ~9.3% in those over >75 
years(1). In the 2001 EuroHeart Survey, MR was second only to aortic stenosis with a 
prevalence of 24.8% of all patients with valvular heart disease(2). 
 MR is classified as primary (or degenerative) when the regurgitation is principally due 
to a structural abnormality of the mitral valve, whether the leaflets, chordae tendinae, papillary 
muscles or mitral annulus as shown in Figure 1.  Secondary (or functional) MR refers to the 
presence of MR without intrinsic MV disease, usually in patients with left ventricular 
dysfunction. FMR is more common than degenerative MR (DMR)(12), and is associated with 
a worse prognosis (compounded by the underlying cardiomyopathy and other comorbidities). 
 
Figure 1. Anatomy of the mitral valve complex 
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FMR can be further classified as either ischemic or non-ischemic in nature (Figure 2). 
Ischemic MR is the more common etiology, and occurs in patients with coronary artery 
disease with regional wall motion abnormalities due to prior myocardial infarction, typically 
resulting in apical and lateral displacement of the posteromedial PM causing tethering of the 
posterior leaflet. Secondary chords on the anterior leaflet may also cause tethering resulting in 
pseudo-prolapse of the anterior leaflet as it slides above the posterior leaflet, producing a 
posteriorly directed MR jet(13).  In contrast to ischemic MR, non-ischemic MR (which is most 
commonly due to idiopathic dilated cardiomyopathy, but can be due to dilated 
cardiomyopathy of any etiology) is characterized by global LV dilatation with increased 
sphericity. In this condition the LV loses its normal “football” shape, becoming more rounded, 
or “basketball”-like. Displacement of both PMs and apical tethering of the chordae tendinae 
and MV leaflets results typically in a centrally directed regurgitant jet(13). LV dilation and 
remodelling in non-ischemic cardiomyopathy results in symmetric MA dilatation greatest in 
the septal-lateral direction that correlates with the severity of ventricular dysfunction(14). 
 
Figure 2. Schematic and echo representation of ischemic MR (top panel), and non-
ischemic MR (bottom panel) 
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The top panel demonstrates tethering of the posterior mitral valve leaflet due to a regional wall motion 
abnormality, as seen on the mid-esophageal long-axis view of a TEE, with an eccentric jet of MR. The bottom 
panel illustrates global dilatation of the left ventricle resulting in displacement of the papillary muscles and a 
wide, central jet of MR in the mid-esophagel two chamber view. 
 
Heart Failure 
Heart failure (HF) is an epidemic and major public health concern with over 500,000 
new cases diagnosed annually worldwide and a prevalence that is expected to increase by 25% 
by 2030(15, 16).  Current management for HF involves pharmacologic therapy with beta-
blockers, angiotensin converting enzyme inhibitors or angiotensin receptor blockers and 
aldosterone antagonists, as described in the recent ACC/AHA Heart Failure Guidelines(17). 
The prevalence of secondary MR in HF patients is high.  In a study of 1256 patients 
with dilated cardiomyopathy of either ischemic or non-ischemic etiology, the prevalence of 
severe MR was 24%(6).  A study of 2057 HF patients with an ejection fraction less than 40% 
from the Duke Cardiovascular Databank noted the presence of moderate to severe or severe 
MR in 29.8%(18).  There is a strong association between secondary MR and all-cause 
mortality and hospitalizations for HF:  In the previously mentioned study of dilated 
cardiomyopathy, severe secondary MR was an independent predictor of death or HF 
hospitalization at median 2.5-year follow-up (adjusted HR: 1.5 [95% CI: 1.2-1.9]), 
independent of left ventricular function(6).  In fact, secondary MR is a powerful predictor of 
death or transplant, even with less severe HF(19).  
Guideline directed medical therapy (GDMT) is the first line of treatment for FMR, and 
consists of aggressive management of HF as per recent guidelines(17). Unfortunately, 
morbidity and mortality of patients with LV dysfunction and FMR remain high despite 
GDMT. In a study of 404 patients with at least mild FMR due to ischemic or non-ischemic 
cardiomyopathy treated with GDMT, cardiac mortality at mean follow-up of 4 years occurred 
in 43% and 45% of patients with moderate and severe MR respectively, compared to only 6% 
with mild MR (P=0.003)(20). The presence of moderate or severe MR was also an 
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independent predictor of new onset HF in those patients with a history of ischemic systolic 
dysfunction (relative risk [95%CI] = 3.2 [1.9–5.2], P=0.0001).  
 
Transcatheter Mitral Valve Leaflet Repair  
Despite the poor prognosis with GDMT, most HF patients with FMR not requiring 
CABG are not referred to MV surgery due to high surgical risk in the setting of multiple 
comorbidities, and the lack of a proven survival benefit(5). In fact, in a review of patients with 
MR treated at the Cleveland Clinic, FMR was more likely to be treated medically rather than 
with surgery, with 47.5% of patients managed medically compared to surgical intervention in 
26.8%. In those patients managed medically 5-year mortality was 50%(21). As a result of the 
under-utilization of surgical therapy due to increased patient risk, transcatheter strategies have 
emerged as potential treatment options for such patients. 
The question remains whether treatment of mitral regurgitation in addition to GDMT in 
HF is beneficial. Recent evidence from the NIH randomized trial in patients with moderate 
ischemic MR randomized to revascularization or revascularization and mitral valve repair did 
not demonstrate a statistically significant difference in the primary endpoint of LV 
remodelling as measured by left ventricular end-systolic volume index. Patients treated with 
mitral valve repair did have a higher incidence of neurologic complications but there were no 
observed differences in mortality or quality of life although the trial was not powered for these 
endpoints(22). It is unclear whether the failure of the trial to show a clinical benefit was 
related to surgical morbidity or sample size. 
Currently, the COAPT Trial of MitraClip vs. Medical therapy in functional mitral 
regurgitation is underway and will attempt to answer this question.  The primary endpoint of 
this randomized trial is rehospitalization for HF at one year, and secondary endpoints include 
mortality, reduction in mitral regurgitation and improvement in quality of life. 
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MitraClip Device 
Transcatheter mitral leaflet repair is a percutaneous technique based on the surgical 
edge-to-edge mitral leaflet repair described by Alfieri (Figure 3) performed using the 
MitraClip(23). The MitraClip (Abbott Vascular, Menlo Park, CA) is a polyester-covered 
cobalt-chromium clip that is inserted via the femoral vein and advanced under trans-
esophageal echocardiographic guidance into the LA following trans-septal puncture (Figure 
4). The clip is opened, positioned above the regurgitant jet and advanced into the LV. It is then 
retracted to grasp the free edges of the mitral leaflets, the grippers are dropped and the clip is 
closed and released. Multiple clips may be safely placed if necessary, with no reported cases 
to date of mitral stenosis. The MitraClip has received CE mark and Health Canada approval, 
and limited FDA approval in the US for treatment of patients with DMR who are at 
prohibitive risk for surgery on the basis of data from the EVEREST II trial(24) and High risk 
registry(25) which were performed in predominantly although not exclusively DMR patients. 
Due to the ongoing randomized clinical trial of MitraClip in FMR, MitraClip is not currently 
FDA approved for this indication. 
 
 
Figure 3. Schematic drawing of surgical Alfieri double orifice repair and MitraClip  
Left panel : artist rendering of a surgical Alfieri repair with sutures 
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Right panel : artist rendering of a MitraClip device in place in the mitral valve creating a 
double orifice mitral valve (Courtesy of Abbott Vascular, Menlo Park, CA) 
 
 
 
Figure 4. Transcatheter mitral valve repair with the MitraClip device (from top left to 
bottom right: MitraClip device; close-up of MitraClip device; MitraClip device in place in jet 
of mitral regurgitation; double orifice mitral valve; MitraClip in place following device 
release) (Courtesy of Abbott Vascular, Menlo Park, CA) 
 
Clinical Results 
The initial safety and feasibility of the MitraClip was confirmed in the EVEREST I 
pilot study of 27 patients. A clip was successfully placed in 24 patients with no procedural 
complications.  MR was successfully reduced in 52% of patients with a result that was 
maintained at 6-month follow up.(8) Following the EVEREST I pilot experience, the 
MitraClip was compared to surgical MV repair in the 278 patient randomized controlled 
EVEREST II trial in relatively low risk patients with 3+-4+ MR. Compared to MV surgery, 
the MitraClip procedure was substantially safer, but not as effective in reducing MR and LV 
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remodelling(24). Moreover, reflecting the early learning curve with this device, acute 
procedural success (MR ≤2+ at discharge) was achieved in only 77% of patients, and 21% of 
patients’ required MV surgery. Nonetheless, with follow-up now to 4 years, NYHA class and 
overall survival were similar in the 2 groups (26). Of note, however, 73% of the patents in this 
trial had DMR, and 27% had FMR. A significant interaction was present between the 
randomized therapy and the primary composite endpoint of death, MV surgery, and 3+-4+ MR 
at both 1 and 4 years according to MR etiology; patients with DMR had significantly 
improved outcomes with MV repair, whereas outcomes were at least as good with the 
MitraClip in patients with FMR(24, 26). 
Since device commercialization in Europe, the MitraClip has been used extensively in 
patients at high risk for MV surgery, more frequently in FMR than DMR(27, 28). In the post-
approval ACCESS-EU registry, the MitraClip was implanted in 567 patients at 14 sites 
between April 2009 and April 2011. The mean logistic EuroSCORE was 23, and 77% of the 
patients had 3+-4+ FMR. The clip implant rate was 99.6%, with multiple clips used in 40% of 
patients. MR was reduced to ≤2+ in 91% of patients, and there were 0 procedural deaths. 
Through 12 month follow-up NYHA class and 6-minute walk distance have substantially 
improved. The MitraClip has also been used with success in HF patients who are non-
responders to CRT (an especially high-risk group), with resultant improvements in MR grade, 
functional capacity, and evidence of left ventricular remodelling(29). 
At present, there are several randomized clinical trials underway addressing the 
question of the use of MitraClip in FMR. Until such data become available there is registry 
data from numerous registries of FMR patients that have demonstrated high rates of 
procedural success and favorable short-term outcomes in patients treated with MitraClip. The 
largest published registries of FMR are summarized in Table 1(10, 30-42).   
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Table 1. International Registry data of MitraClip in predominantly FMR 
 
The largest published registry to date is the Transcatheter Mitral Valve Interventions 
(TRAMI) Registry(30).  Among 1,064 patients treated with the MitraClip at 20 German 
centers, the median age was 75 years; 87% had NYHA III/IV HF symptoms; 69% had LVEF 
<50%; FMR was present in 71% of patients; and the median STS mortality score was 10. 
Procedural success was achieved in 95% of patients, with no procedural deaths. At ~3 months 
of follow-up, 12% of patients had died and 12% had been hospitalized for HF, although 66% 
remained in NYHA class I/II.  
Similarly, in the 25-center, 8-country 2011–2012 European Sentinel Pilot Registry, 72% of 
628 MitraClip-treated patients had FMR, 86% had NYHA class III/IV symptoms, and the 
mean EuroSCORE was 20.4(31).  Acute procedural success was high (95.4%), with multiple 
clips used in 39% of patients. In-hospital mortality (2.9%) and 1-year mortality (15.3%) were 
similar in patients with FMR and DMR, although rehospitalization for HF was more common 
in the FMR group (25.8% vs. 12.0%, p=0.009). At 1 year severe MR was present in only 6% 
of patents. Pooled data from the EVEREST II High-risk Registry and US REALISM registry 
Table 1. Large-scale published registries of the MitraClip: baseline characteristics and acute procedural success 
 
Registry N Mean age (years) Male 
Mean or 
median risk 
NYHA 
Class III/IV 
Mean 
LVEF 
FMR 
etiology 
≤2+ MR 
post 
Multiple 
clips 
Procedural 
success¶ 
TRAMI 1064 75 62% 10%* 87% † 71% 96% 1.5 mean 95% 
ACCESS-EU 567 78 64% 23%** 85% †† 77% 91% 40% 99.6% 
European Sentinel 628 74 63% 20%** 86% 43% 72% 98% 37% 95% 
EVEREST and REALISM 351 76 61% 11%* 85% 48% 70% 86% 39% - 
GRASP 171 71 62% 7%* 81% 37% 78% 93% 41% 99% 
MARS 142 71 64% 17%** 68% 47% 54% 77% 47% 94% 
Taramasso et al 109 69 84% 22%** 82% 28% 100% 87% 65% 99% 
Mitra-Swiss 100 77 67% 17%** 82% 48% 62% 85% 40% 85% 
French multicenter 62 73 72% 19%** 81% 40% 74% 88% 17% 95% 
Treede et al 202 75 63% 44%** 98% 44% 65% 92% 35% 92% 
Bozdag-Turan et al 121 77 69% 11%* 96% 42% 59% 99% 28% 97% 
Rudolph et al 104 74 62% 36%** 100% 43% 66% 92% 38% 92% 
Braun et al 119 71 67% 28%**‡ 86% 35%‡ 35%‡ - - 86% 
Neuss et al 157 74 67% 22%** 100% 41% 73% 100% 16% 98% 
* By the Society for Thoracic Surgery score; ** By the logistic EuroScore; †LVEF ≤50% in 69% of patients; ††LVEF ≤40% in 53% of patients;                
‡In patients with FMR; ¶According to the registry protocol definition, which varied per study.  
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have been recently published in which the MitraClip was used in 351 patients with an STS 
score or surgeon-predicted operative mortality of ≥12% (70% of whom had FMR)(32).  By 
paired echocardiographic core lab analysis MR was ≤2+ in 89.7% of patients at discharge and 
in 83.4% of patients at 1 year. Mortality was 4.8% at 30 days and 22.8% at 1 year. LV end-
diastolic and end-systolic dimensions decreased through 1 year follow-up, the physical and 
mental components of the SF-36 quality-of-life score improved, and the proportion of patients 
with NYHA class III/IV symptoms was reduced from 82.1% at baseline 17.1% at 1 year. The 
rate of hospitalizations for HF was significantly reduced in the year after compared to the year 
before the MitraClip (median per patient 0.41 vs. 0.79, p<0.0001). All outcomes were 
directionally consistent in patients with FMR and DMR. The MitraClip has also been used 
with success in HF patients who are non-responders to cardiac resynchronization therapy 
(CRT), an especially high-risk group, with resultant improvements in MR grade, functional 
capacity, and LV remodelling(29). In this study, patients remained in NYHA class III-IV 
despite CRT and were treated with MitraClip to address significant mitral regurgitation.  
Following the MitraClip procedure there was progressive improvement in NYHA Class and 
LV remodelling at both 6 and 12 months.  
The role of MitraClip in the treatment of patients with FMR has recently been 
addressed by societal guidelines. The 2012 ESC/EACTS valve guidelines provide a class IIb 
(level of evidence C) recommendation to consider use of the MitraClip in patients with 
symptomatic severe FMR despite GDMT and CRT who are inoperable or at high surgical risk 
with life expectancy >1 year(4). The 2012 ESC HF guidelines similarly note that percutaneous 
edge-to-edge repair may be considered in order to improve symptoms in patients with an 
indication for valve repair that are judged inoperable or at unacceptably high surgical risk(43). 
Finally, the 2013 ACC/AHA heart failure guidelines provide a class IIb (level of evidence B) 
recommendation to consider use of the MitraClip in patients with symptomatic severe FMR 
despite GDMT after “careful candidate selection”(7). 
Given the enthusiasm for such new technology in the field of cardiology, an 
understanding of the clinical impact and the economic ramifications of percutaneous treatment 
of secondary MR in these patients is critical to ensuring appropriate use of what remains 
limited resources. 
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Economic Impact of Heart Failure 
In addition to the impact on mortality and morbidity, HF places a major strain on 
health care resources, accounting for 2–5% of the total health-care budget in most developed 
countries(44).  In 2012, the economic burden of HF was estimated to be $3.9 billion in 
Canada(45).  The total cost of HF management consists of several components, including 
hospital management for acute decompensation, physician and outpatient visits, and medical 
therapy. However, device-based treatments, such as implantable defibrillators, biventricular 
cardiac pacing devices for CRT, and ventricular mechanical circulatory support, have now 
emerged as a central and costly part of HF treatment.  Health economic analysis or cost-
effectiveness analysis has been increasingly used in countries such as the United Kingdom, 
Australia and Canada to understand the impact of health technologies prior to their widespread 
adoption. Such analysis employs thresholds for decision of cost-effectiveness, which in 
Canada is between $20,000-$100,000 per quality adjusted life year (QALY) gained(46). 
Expensive technology is not new to the field of heart failure and devices such as CRT 
have previously undergone similar assessments of cost-effectiveness analyses.  A cost-
effectiveness study based on data from the randomized COMPANION trial compared the 
costs of optimal medical therapy with those of CRT with pacing only (CRT-P) and CRT with 
defibrillator (CRT-D).  Their analyses demonstrated an ICER of $19,600 per QALY for CRT-
P and a ICER of $43,000 for CRT-D, both of which were felt to be in the range of reasonable 
costs for a new therapeutic intervention(47). 
 
  
Methods 
The goal of this study was to evaluate the outcomes of HF patients with significant 
FMR treated with the MitraClip at our institution, compare these outcomes with a cohort of 
medically treated patients and finally to evaluate the cost-effectiveness of this therapy. 
Study Objectives 
1. Prospectively evaluate the outcomes of a cohort of patients with significant functional 
regurgitation and congestive HF treated with the MitraClip at our institution 
 
2. Compare the outcomes of the MitraClip cohort with a historical cohort of patients with 
significant MR treated with medical therapy 
 
3. Estimate the cost-effectiveness of MitraClip therapy compared to medical therapy in 
patient with significant MR and HF 
 
Study Hypotheses 
1. HF patients with significant MR treated with MitraClip will have lower rates of 
recurrent hospitalizations for HF compared to those treated with medical therapy. 
2. Therapy with the MitraClip will be cost-effective compared to medical therapy in 
patients with HF and significant MR. 
Study Design 
The study was comprised of two phases: a comparison of propensity matched 
populations from an observational study of patients with HF and MR that were treated with 
either medical management or the MitraClip; and an economic model.  Results of the 
observational study were used to estimate parameters for the economic model.   The local 
Ethics Committee approved the study (Project #12-1403). 
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Observational Study 
MitraClip Cohort 
 This prospective cohort was comprised of patients treated with the MitraClip (Abbott 
Vascular, Menlo Park, CA) at the Montreal Heart Institute from 2010 - 2013.  Indication for 
the procedure was determined by local institutional practice and following consultation with 
the treating physician, cardiologist and cardiac surgeon. Eligible patients had symptomatic or 
asymptomatic moderate-to-severe (3+) or severe (4+) MR and were considered high risk for 
surgical intervention following multidisciplinary team discussion.  Patients underwent trans-
thoracic and trans-esophageal echocardiography to evaluate anatomical suitability. Exclusion 
criteria for the procedure included the following:  mitral valve area <4 cm2 by planimetry, 
significant valvular or annular calcification, or visible thrombus in the left atrium. Procedures 
were performed as previously described(9, 48), and all patients signed informed consent and 
were approved under the Health Canada Special Access program to undergo the intervention. 
Data was collected on the following demographic variables: age, gender, left ventricular 
ejection fraction, history of ischemic heart disease, atrial fibrillation, hypertension, previous 
coronary artery bypass graft surgery, previous percutaneous coronary intervention, 
implantable cardioverter-defibrillator, cardiac resynchronization therapy, diabetes, and therapy 
with beta-blockers, ACE inhibitors, diuretics, angiotensin receptor blockers, and 
spironolactone; as well as mortality, rehospitalization for CHF and visits to the emergency 
room. 
 
Medical Management Cohort 
 This retrospective comparator group consisted of medically managed patients with 
moderate to severe and severe (3-4+) MR followed at the Heart Failure Clinic at the Montreal 
Heart Institute from 2008-2010. The HF Clinic maintains a database of patients with HF and 
captures demographic data, medical therapy, diagnostic tests, interventions, rehospitalizations, 
hospital and ER visits, and mortality. Patients’ entry into the cohort was considered to be the 
date that significant MR was diagnosed by echocardiography. 
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The medical cohort was less symptomatic with the majority of patients reporting 
NYHA class II symptoms, compared to the predominantly class IV symptoms in the MitraClip 
group. Given the significant differences in baseline functional class between the MitraClip and 
medical management cohorts, it was not possible to include NYHA class in the propensity 
matching.  
Clinical Outcomes  
Clinical outcomes of interest in the matched cohort included the following; emergency 
room (ER) visits, rehospitalizations for HF, mitral valve surgery and mortality.  For the 
MitraClip cohort, this data was obtained from patient interviews and chart review.  For the 
medical management cohort, this data was obtained directly from the HF Clinic database.  
Data for each outcome was tabulated for the individual cohorts over the follow up period to 
calculate a rate and then probability of the outcome per patient. For example, a total of 100 
readmissions for HF over a one-year period in the MitraClip cohort of 50 patients would be 
interpreted as a rate of 2 admissions per patient per year. 
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Statistical Analysis 
To create a matched cohort, medical management patients were matched to those 
treated with the MitraClip using a propensity score. A multivariate logistic regression model 
with presence of MitraClip as the dependent variable included the following independent 
variables: age, gender, left ventricular ejection fraction, history of ischemic heart disease, 
atrial fibrillation, hypertension, previous coronary artery bypass graft surgery, previous 
percutaneous coronary intervention, implantable cardioverter-defibrillator, cardiac 
resynchronization therapy, diabetes, and therapy with beta-blockers, ACE inhibitors, diuretics, 
angiotensin receptor blockers, and spironolactone. Propensity scores (predicted probability of 
having MitraClip) were obtained for each subject with MitraClip (MC) and medical therapy 
(MM). Absolute differences between propensity scores were computed for each pair of MC 
and MM subjects. Each MC subject was matched with the MM subject that yielded the 
smallest absolute difference in a 1:5 greedy matching scheme, matching was performed with 
replacement.  
Continuous variables were presented as means and standard deviations.  Categorical 
variables were presented as frequencies and percentages.  Survival in each cohort was 
evaluated using Kaplan-Meier curves and differences in survival were compared using a log-
rank test. 
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Economic Model 
 An economic model was developed in Excel (Microsoft Corporation, Redmond, WA, 
USA) to estimate the costs, life-years and quality-adjusted life years (QALY) for the studied 
patients. This data was then used to calculate the incremental cost per QALY gained and per 
life-year gained. 
 The model followed a hypothetical cohort of HF patients with significant MR in one-
month time increments from age 75 years until death or age 85.  Patients were treated with 
either standard medical therapy (including cardiac resynchronization therapy as indicated) or 
the MitraClip device. We programmed the model inputs such that the estimates of survival, 
emergency room (ER) visits, hospitalizations and rates of mitral valve surgery were the same 
as the results obtained in the observational study. Outcomes of interest were life expectancy 
(measured in years), QALYs, and costs (reported in 2013 Canadian dollars) and the 
incremental cost-effectiveness ratio. The model was analyzed from the perspective of the 
Canadian publicly funded health care system. All health outcomes and costs were discounted 
at 5% per year as per the recommendations of the Canadian Agency for Drugs and 
Technologies in Health(49). Discounting is performed to standardize flows of costs and 
benefits that occur at different points in time.  For external model validation, we compared 
outcomes of the modeled cohort over time with outcomes in independent registries(6, 10). 
 
Model Overview: Data and Assumptions 
 We constructed a decision model of symptomatic severe MR to simulate disease 
progression and added MitraClip as a treatment option (see Figure 5).  In the first month of the 
model, at time zero, patients in the MitraClip group underwent the procedure and may have 
survived or died.  Additionally, in that first month they may have also experienced a 
complication related to the procedure, mitral valve surgery, re-intervention with the MitraClip, 
hospitalization for congestive heart failure (CHF) and/or visits to the ER. In every subsequent 
monthly cycle, MitraClip patients may have died, undergone mitral valve surgery, had re-
intervention, or have had ER visits or hospitalizations for HF. For the medical therapy group, 
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in any one-month cycle, patients may have undergone mitral valve surgery, been hospitalized 
for heart failure, visited the ER or died.  
 
 
 
Figure 5. Decision Model for Cost-effectiveness Analysis 
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We estimated mortality and peri-procedural complication rates after MitraClip using 
data from the observational study. The probability of death, hospitalization for heart failure, 
ER visits, and mitral valve surgery in the medical cohort were likewise obtained from the 
observational study.  Mortality was extrapolated using parametric survival models for a time 
horizon of ten years.  An exponential, log-normal and weibull extrapolation were performed, 
the weibull was chosen as it was a better fit for the data according to the Akaike information 
criterion (AIC)(50). 
During each cycle of the model, cohort specific probabilities calculated from actual 
event rates, for heart failure hospitalizations and ER visits were applied such that all patients 
alive remained at risk for these outcomes.  The cohort-specific probability for mitral valve 
surgery was applied to both groups during the first twelve months only. Model parameters are 
detailed in Table 2.  The time horizon for the model was ten years.  Model assumptions for the 
base case analysis included; baseline NYHA for the medical therapy cohort was equivalent to 
that of MitraClip patients prior to intervention, NYHA class was increased in both cohorts by 
one class every two years, and the probability of mitral valve surgery applied only in the first 
year for both cohorts.  
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Table 2. Health Utilities and Event Rates with Ranges used in Base Case (Mean Value) 
and Probabilistic Sensitivity Analyses 
 
 Mean 
Value 
Standard 
Error 
Distribution Parameters 
(α, β)  
Reference 
Utilities      
NYHA Class I 0.900 0.037 Beta (58.3, 6.5) (51) 
NYHA Class II 0.830 0.006 Beta (3252.3, 666.1) (51) 
NYHA Class III 0.740 0.009 Beta (1756.9, 617.3) (51) 
NYHA Class IV 0.600 0.026 Beta (212.4, 141.6) (51) 
Utility decrement MitraClip 0.043 0.042 Beta (0.96, 21.4) (52) 
Utility decrement Surgery 0.079 0.074 Beta (0.97, 11.3) (53) 
Utility decrement 
Hospitalization 
0.064 0.001 Beta 
(3776.1, 55690.6) 
(54) 
Utility decrement ER visit 0.002 0.001 Beta (3.99,1991.0) (54) 
      
Event Rates      
Hazard ratio (Survival) 0.392 0.361 Log normal (-0.94, 0.36) Clinical data 
      
MitraClip Cohort (first 30 days)      
Mitral valve surgery 0.043 0.004 Beta (95.6, 2103.4) Clinical data 
CHF Hospitalization 0.065 0.007 Beta (93.4, 1338.9) Clinical data 
ER visits 0.064 0.006 Beta (93.5, 1367.3) Clinical data 
Complications 0.043 0.004 Beta (95.6, 2103.4) Clinical data 
      
MitraClip Cohort (Follow up)      
Mitral valve surgery 0.002 0.000 Beta (99.8, 49799) Clinical data 
CHF Hospitalization 0.014 0.001 Beta (98.6, 6965.4) Clinical data 
Length of Hospital Stay (days) 10.6 5.6 Normal  Clinical data 
ER visits 0.007 0.001 Beta (99.3, 14108) Clinical data 
      
Medical therapy Cohort      
Mitral valve surgery 0.013 0.001 Beta (98.7, 7544.2) Clinical data 
CHF Hospitalization 0.034 0.003 Beta (96.5, 2706.4) Clinical data 
Length of Hospital Stay (days) 9.0 6.6 Normal  Clinical data 
ER visits 0.036 0.004 Beta (96.4, 2590.4) Clinical data 	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Costs 
 Detailed resource utilization and costs were collected for the MitraClip and medical 
therapy cohorts, as outlined in Table 3.  Costs were calculated using the most important cost 
drivers from clinical data including diagnostic evaluation costs directly incurred as a result of 
the MitraClip procedure, procedural costs, and inpatient treatment costs at a large tertiary care 
hospital in Montreal (Montreal Heart Institute).  The cost of MitraClip is per procedure 
(irrespective of the number of clips used).  Follow-up costs included protocol driven visits and 
tests.  Costs of hospitalizations and emergency room visits were obtained from the Montreal 
Heart Institute. Data on costs for the medical therapy cohort were obtained by reviewing 
outpatient hospital clinic visits, emergency room visits and hospitalizations recorded in the 
Heart Failure Clinic Database. Costs are summarized in Table 3. Hospitalization costs at other 
centers were assumed to be equal to those incurred at our tertiary care center in 2013. 
Table 3. Health Care Resource Costs 
Cost Input Mean Cost (CDN $) 
Standard 
Error 
Gamma 
Parameters 
            Data Source 
 
MitraClip Cohort Costs 
    
     
cost_MC_investigations 672.37 336.18 (4, 168.09) MHI billing 
cost_MC_device 30000.00 15000.00 (4, 7500) MHI billing 
cost_MC_procedure 19689.70 9844.85 (4, 4922.43) MHI billing 
cost_MC_Followup_Month 39.36 19.67 (4, 9.84) MHI billing 
cost_MC_FU_year1 912.10 456.05 (4, 228.03) MHI billing 
cost_MC_Reintervention 49689.70 24844.85 (4, 12422.43) MHI billing 
cost_CHFadmission_ICU 3647.50 1823.75 (4, 911.28)  
cost_CHFadmission_ward 1669.80 834.90 (4, 417.25)  
cost_MVSurgery 
(Replacement) 20375.00 10187.50 (4, 5093.75) 
MHI billing 
cost_ERvisits 315.41 157.70 
 
(4,78.85) 
MHI cath lab 
billing 
cost_HFClinic_visits 133.84 66.92 
 
(4, 33.46) 
MHI cath lab 
billing 
     
Medical Management Costs     
cost_MM_management_ 
annual 
$3,647.50 Gamma (4, 129.61) MHI billing 
cost_MM_management_ 
month 
$1,669.80 Gamma (4, 10.80) MHI billing 	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Utilities 
 Quality adjusted life years (QALY) (life expectancy adjusted for quality of life of the 
health state experienced) were calculated for each patient in the alive state using published 
health utilities, which measure quality of life from a 0 (dead) to 1 (perfect health) scale, for 
heart failure according to NYHA Class(51). We assumed that patients in the medical therapy 
cohort remained in NYHA Class III-IV for the duration of the model.  The NYHA Class 
assigned to patients treated with MitraClip during the first year of follow-up was based on 
actual data. For projected time intervals beyond the clinical study data, an assumption was 
made that patients would deteriorate by one NYHA Class every two years.  
 Short-term utility decrements (i.e. disutility) for the MitraClip procedure were 
approximated using published decrements for percutaneous coronary intervention(55) and 
were applied in the first cycle of the model.  A utility decrement for mitral valve surgery 
obtained from the literature(53) was applied to both groups for the first year of the model only. 
Utility decrements were also applied for heart failure hospitalizations(54) and emergency 
room visits(56) according to the proportion of patients alive and at risk. 
Analysis 
We performed extensive deterministic sensitivity analyses to explore the impact of 
uncertainty in key parameters on the analysis results. A probabilistic sensitivity analysis to 
further characterize uncertainty in model parameters was performed using 10000 simulations. 
A beta distribution was applied to all probabilities and utilities, gamma distributions to all 
costs, and a log normal distribution for all hazard ratios (see Table 2). Results are represented 
in the form of a scatter plot and cost-effectiveness acceptability curve (CEAC) representing 
the probability of the MitraClip being cost-effective over a range of different willingness to 
pay thresholds 
 
 
 
  
Results 
Observational Study of MitraClip 
 A total of 50 consecutive patients underwent the MitraClip procedure from December 
2010 until March 2013 and their baseline characteristics are described in Table 4. The average 
age was 75.4±9.1 years and, 74% were male. The majority of patients (78%) had a previous 
history of ischemic heart disease, with 52% (n=26) having had previous CABG and 40% 
(n=20) previous coronary intervention (PCI).  Atrial fibrillation was present in over half the 
cohort (n=29) and device therapy was used in 54% (n=27) of patients.  Patients had 
symptomatic heart failure, 98% were NYHA class III or IV.  MR severity was assessed as 
3+or 4+ in all patients and the underlying etiology was functional in 90% of cases.  A small 
subset of patients had high-risk degenerative MR (n=5).  The mean ejection fraction was 38.3 
± 15.8%. 
 
MitraClip Procedure 
 The MitraClip procedure was performed under general anesthetic using trans-
esophageal guidance as previously described (9). MitraClip device placement was successful 
in 96% of patients (n=48).  Failure to place a device occurred in two patients in whom there 
was severe restriction of a shortened posterior leaflet that precluded grasping.  MR severity 
was reduced to ≤ 2+ in 94% (n=47) of the initial cohort.  Two clips were used in 71% (n=34) 
on patients, with one clip in the remaining 29% (n=14). 
 
30-day Major Adverse Events 
 Four patients (8%) died within 30 days of the MitraClip procedure. All were 
considered procedure-related but none occurred intra-procedurally.  The two patients with 
unsuccessful MitraClip procedures (i.e., no clip implanted) died due to progressive heart 
failure and low cardiac output.  A third patient had single-leaflet device attachment 48 post-
procedure requiring surgical mitral valve replacement and subsequently died due to post-
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operative complications.  The fourth patient died 48 hours post-intervention due to an acute 
intra-cerebral haemorrhage on warfarin for chronic atrial fibrillation. An additional patient 
required surgical mitral valve replacement two days post-procedure due to persistent severe 
MR in the setting of a mitral valve cleft, with an uneventful recovery.  No patients were lost to 
follow up however patients were entered into the cohort as the MitraClip procedure was 
performed from 2010-2013 therefore the individual patient follow up is variable depending on 
when they underwent the procedure. 
 
Medical Management Cohort 
The medical management cohort was comprised of 42 patients that were matched to the 
MitraClip group on the basis of comorbidities and medical therapy. The baseline 
characteristics of the medical management cohort are described in Table 3.  In comparison to 
the MitraClip cohort, the patients were younger, with a mean age 68.2 ±15.5 years.  
Comorbidities were similar however there were lower rates of ischemic heart disease (71%), 
CABG (48%) and previous PCI (33%).  Patients were less symptomatic, with the majority of 
patients being NYHA Class II or III and but this parameter was not used in the matching 
process.  Echocardiographic assessment demonstrated MR severity of 3+ or 4+ in all patients 
however the mean ejection fraction of 31.8 ± 13.6% was lower than that measured in the 
MitraClip cohort.  Accordingly, there were higher rates of device therapy in this cohort, 59% 
with pacemaker or implantable defibrillator. 
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Table 4. Baseline Characteristics of MitraClip and Medical Management Cohorts 	  	   MitraClip	  Cohort	  (n=50)	   Medical	  Management	  	  Cohort	  	  (n=42)	  	   	   	  Mean	  age	  (years)	   75.4±	  9.1	   68.2	  ±15.5	  %	  Males	   74%	  (37)	   77%	  (33)	  	   	   	  Mitral	  Regurgitation	  Severity	   	   	  3+	   58%	  (29)	   76%	  (32)	  4+	   42%	  (21)	   24%	  (10)	  	   	   	  Ischemic	  Heart	  Disease	   78%	  (39)	   71%	  (30)	  Atrial	  Fibrillation	   58%	  (29)	   64%	  (27)	  Hypertension	   58%	  (29)	   57%	  (24)	  Diabetes	   42%	  (21)	   31%	  (13)	  Previous	  CABG	   52%	  (26)	   48%	  (20)	  Previous	  PCI	   40%	  (20)	   33%	  (14)	  Pacemaker/ICD	   34%	  (17)	   59%	  (25)	  Cardiac	  Resynchronization	  Therapy	  (CRT)	   20%	  (10)	   14%(6)	  Left	  Ventricular	  Ejection	  Fraction	  (%)	   38.3	  ±	  15.8	   31.8	  ±	  13.6	  	   	   	  NYHA	  Class	  at	  Baseline	   	   	  II	   2%	  (1)	   74%	  (31)	  III	   32%	  (16)	   21.4%	  (9)	  IV	   66%	  (33)	   0%	  (0)	  	   	   	  	   	   	  Medical	  Therapy	   	   	  ACE	  Inhibitors	   44%	  (22)	   43%	  (18)	  Beta	  Blocker	   86%	  (43)	   83%	  (35)	  Diuretics	   88%	  (44)	   86%	  (36)	  Angiotensin-­‐Receptor	  Blockers	  	   28%	  (14)	   26%	  (11)	  Aldosterone	  Antagonists	   50%	  (25)	   62%	  (26)	  	  CABG	  denotes	  coronary	  artery	  bypass	  graft;	  PCI,	  percutaneous	  coronary	  intervention;	  ICD,	  implantable	  cardioverter-­‐defibrillator;	  NYHA,	  New	  York	  Heart	  Association;	  ACE,	  angiotensin	  converting	  enzyme	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Table 5. Comparison of Outcomes in MitraClip and Medical therapy Cohorts at 30 days 
and 1 year 	   MitraClip	  (n=50)	   Medical	  
management	  
(n=42)	  
Outcome	   30	  days	   12	  months	   12	  months	  	  All	  –	  cause	  Mortality	   	  8%	  (4) 	  18%	  (9)	   	  24%	  (10)	  	  Mitral	  Valve	  surgery	   	  4%	  (2)	   	  6%	  (3)	   	  21%	  (9)	  	  #	  CHF	  Hospitalizations/patient	   	  0.06	   	  0.16	   	  0.57	  	  #	  ER	  visits/patient	   	  0.06	   	  0.08	   	  0.60	  	  	  CHF	  denotes	  congestive	  heart	  failure;	  ER,	  emergency	  room	  	  	  	  
Clinical Follow Up 
Clinical follow up of patients in both cohorts at 12 months are shown in Table 5.  All-cause 
mortality was 18% and 24% in the MitraClip and medical management cohorts respectively. 
The number of hospitalizations for heart failure was 0.16 and 0.57 per patient in each group.  
Emergency room visits at 12 months were 0.08 and .60 per patient. Longer-term follow up 
was available in the MitraClip and medical management cohorts at a mean of 22±15 and 
33±21 months respectively.  At these time points, all-cause mortality was 21% in the 
MitraClip cohort and 42% in the medical management cohort, hazard ratio 0.39, 95% 
confidence interval [CI]: 0.19 to 0.79, p=0.007.  Kaplan-Meier survival curves are plotted in 
Figure 6, with Weibull extrapolations for a time horizon of ten years overlaid in Figure 7.  	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Figure	   6.	   Kaplan-­‐Meier	   survival	   curves	   for	   patients	   treated	   with	   MitraClip	   and	  
medical	  management	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Figure 7.  Kaplan-Meier curves for MitraClip and Medical Management overlaid with 
Weibull extrapolations to ten years 
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Cost-Effectiveness of MitraClip vs. Medical Therapy 
 Costs of the MitraClip device and procedure  (approximately $80,000 CDN) were 
partially offset ($30,000) by lower hospitalization, ER visits and mitral valve surgical costs 
when compared to medical therapy. 
 Table 6 summarizes the discounted results of the cost-effectiveness analysis. Under the 
above assumptions, the discounted cost of a MitraClip per patient was $88,200.00 compared to 
$35,600.00 for medical therapy over a ten-year time horizon.  The discounted life years gained 
was 3.60 in the MitraClip cohort and 1.87 in the medical therapy cohort. Given an incremental 
difference in QALYs of 1.63 this results in an ICER of $32,300.00 per QALY gained. 
 
Table 6. Economic Outcomes for MitraClip and Medical Therapy 	  	   Medical	  Management	   MitraClip	  Therapy	   Incremental	  Difference	  	   	   	   	  Costs	   $35,600.00	   $88,200.00	   $52,600.00	  Life	  Years	  (LY)	   1.87	   3.60	   1.74	  Quality-­‐adjusted	  life	  years	  (QALY)	   1.13	   2.76	   1.63	  	   	   	   	  Incremental	  cost-­‐effectiveness	  ratio	  of	  MitraClip	  to	  medical	  management	  $/LY	  gained	  $/QALY	  gained	  
	   	   	  	  	  $30,300.00	  $32,300.00	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Sensitivity Analyses 
 The model was robust for the majority of variables on one-way sensitivity analyses, as 
shown in the tornado diagram, Figure 8.  The model was sensitive to changes in the hazard 
ratio for survival, and time horizon with the MitraClip remaining cost-effective (assuming a 
threshold of $100,000 per QALY gained(57)) at the upper 95% CI of the hazard ratio, 0.795 
however with an increase in the ICER to $66,300.00. At the time horizon of two years the 
ICER increased to approximately $89,000.00 suggesting that overall life expectancy has an 
impact on the cost-effectiveness. In the absence of an improvement of quality of life in those 
treated with the MitraClip the ICER also increased but remained below the threshold of  
$100,000.00 as displayed in the tornado diagram.  The major incremental cost drivers in the 
model were implant costs (+$50,000.00 CDN) and disease management costs ($11,500.00 
CDN) over the time horizon of the model. One-way sensitivity analyses showed that shorter 
length of hospital stay (2 vs. 4 days) for the procedure and place of hospitalization (critical 
care unit vs. regular ward) had a minor impact on the incremental costs.   
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Figure 8. Tornado diagram of one-way sensitivity analysis 
The tornado diagram above illustrates the results of the one-way sensitivity analysis of the 
model. The midpoint of the bar graphs represents the ICER of the base case analysis, those 
values in blue represent an ICER less than the base case while those in red, an ICER higher 
than the base case analysis.  
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 A probabilistic sensitivity analysis (PSA) to further characterize uncertainty in model 
parameters was performed using 10000 simulations. The PSA demonstrated that treatment 
with the MitraClip compared with medical therapy was cost-effective in 67% of simulations 
using a willingness-to-pay threshold of $50,000 and in 95% of simulations using a 
willingness-to-pay threshold of $100,000 (Figure 9 and 10).   
 
 
Figure 9. Probabilistic sensitivity analysis (scatter plot) of cost-effectiveness of MitraClip 
compared to medical management 
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Figure 10. Cost-effectiveness acceptability curve for MitraClip therapy compared to 
medical therapy in heart failure patients with significant mitral regurgitation 
 
The cost-effectiveness acceptability curve above demonstrates the likelihood of MitraClip 
being cost-effective, based on the data generated by the probabilistic sensitivity analysis, and 
depending on the willingness to pay of the healthcare system.  In the setting of a willingness to 
pay of $50,000 for a new treatment, therapy with MitraClip is cost-effective in 67% of cases 
of patients treated.  In a scenario where the healthcare system is willing to pay $100,000 for a 
new therapy, MitraClip would be cost-effective in 95% of cases.  
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Discussion 
Summary 
This cost-effectiveness modelling study was based on data from heart failure patients 
with significant MR treated in a clinical setting with either medical management or MitraClip 
therapy. In this study, therapy with MitraClip was found to be cost-effective with an ICER of 
$32,300.00 per QALY. This result was driven primarily by an improvement in mortality, 
however patients treated with MitraClip also had lower rates of re-hospitalization for heart 
failure and fewer visits to the emergency room. 
Hospitalizations for heart failure with mitral regurgitation 
The presence of FMR in patients with left ventricular dysfunction is an independent 
risk factor for re-hospitalization for heart failure and mortality, and this risk is further 
increased in those with moderate or severe MR(6). GDMT is the treatment of choice for such 
patients however even in the presence of optimal medical therapy; MR is associated with only 
a 50% survival at 4 years for those with moderate or severe MR. Furthermore, the presence of 
moderate or severe MR is an independent predictor of recurrent heart failure (RR 3.2, 95% CI 
1.9–5.2, P<0.0001)(20).   
MitraClip has been previously used in high-risk patients and those with FMR. The 
EVEREST II High Risk Study was performed in those patients felt to be at high surgical risk 
as estimated by a STS (Society of Thoracic Surgeons) Score >12%.  In this study, 59% of 
patients had FMR and the mean LVEF was 54%.  Patients were treated with the MitraClip to 
reduce MR with procedural success achieved in 83%.  At 1 year, MR reduction was sustained 
in 79% of patients with FMR. The number of patients with CHF hospitalizations also 
decreased significantly from 42% (33 of 78) in the 12 months before the MitraClip procedure 
to 16% (12 of 75) (p<0.02) in the 12 months after discharge after the MitraClip procedure, a 
45% reduction(58).  We found similar results in our matched cohort, with 0.57 admissions per 
patient/year in the medical management group compared to 0.16 admissions per patient/year 
in the MitraClip group. 
  36 
Survival benefit of treatment of mitral regurgitation 
The presence of MR is known to negatively impact survival in patients with heart 
failure with little improvement with medical therapy alone. Despite this fact, it is unclear 
whether surgical or transcatheter valve repair can actually improve survival.  Initial results 
with surgical undersized mitral valve annuloplasty (MVA) were promising with symptomatic 
improvement in the majority of patients(59).  This enthusiasm was somewhat dampened 
however when follow up data on patients treated with annuloplasty demonstrated that there 
was no mortality benefit from surgery in patients with left ventricular dysfunction and 
MR(60).  This retrospective study compared outcomes of patients undergoing MVA to 
propensity-matched patients treated with medical therapy with the goal of identifying 
predictors of mortality or use of mechanical left ventricular support.  The presence of coronary 
artery disease was found to be a risk factor for death, and the use of medical therapy for heart 
failure was associated with a reduced risk of mortality. Mitral valve annuloplasty had no 
impact on reducing mortality(60). 
More recently, a retrospective study evaluated the impact of transcatheter mitral repair 
with MitraClip, surgical treatment or conservative medical management on survival in high-
risk patients with predominantly FMR. This study compared 139 consecutive patients with 
high-risk MR treated with MitraClip to a surgical comparator group  (n=53) and patients 
management medically (n=59).  Patients were propensity matched for comorbidities and 
surgical risk although despite this, the surgical risk was highest in those treated with 
MitraClip.  At a follow up of one year, survival was similar in the MitraClip and surgical 
treatment groups (85.8% and 85.2%, respectively) but significantly lower in those treated 
conservatively (67.7% survival at one year); resulting in a hazard ratio of 0.41, 95% 
confidence interval [CI]: 0.22 to 0.78, p < 0.006 for MitraClip therapy (61).  These results are 
very similar to those in our study, which demonstrated a hazard ratio of 0.39 95% CI: 0.19 to 
0.79, p=0.007. 
To further clarify the hypothesis that therapy with MitraClip is associated with 
improved survival compared to conservative medical management, randomized trials are 
currently underway in the United States, and Europe with the results anticipated in 2017. 
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Cost-effectiveness of MitraClip compared to medical management 
This cost-effectiveness analysis was performed to examine the cost utility of the 
MitraClip in high-risk patients with predominantly FMR. This analysis demonstrates that as 
much as 38% of MitraClip procedure and device costs may be offset by reductions in 
hospitalizations, ER visits and mitral valve surgeries compared to medical therapy.  Given the 
Canadian societal willingness to pay threshold of $20,000 - $40,000(46), MitraClip is cost-
effective with a deterministic ICER of $32,300 per QALY gained and median probabilistic 
ICER of just under $50,000 CDN per QALY gained. Our analysis is unique in that it utilizes a 
propensity-matched cohort of patients with heart failure and FMR in order to minimize 
differences in patient populations undergoing each treatment. The model was most influenced 
by the hazard ratio for survival, demonstrating that the therapy is not cost-effective in the 
absence of a survival benefit.   
Our results are similar to an analysis of the MitraClip published from the perspective of 
the National Health Service in the United Kingdom.  This evaluation utilized data from the 
high-risk registry of EVEREST to create a decision model.  Our results are consistent with this 
analysis, which demonstrated that treatment with the MitraClip was cost-effective in high-risk 
patients.  The UK model was found to be most sensitive to the time horizon chosen rather than 
device or procedure cost(62). 
 A recently published cost-effectiveness study of MitraClip and medical treated patients 
found similar results to our analyses. This propensity matched cohort analysis also compared 
patients treated with MitraClip to those on medical treatment alone and demonstrated that 
treatment with MitraClip was cost-effective with an ICER of 5000-8000 euros/QALY(63). 
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Significance of Study Results 
Heart failure now has an increasing number of treatment options ranging from GDMT to 
advanced heart failure therapies such as defibrillators, CRT, left ventricular assist devices, and 
transcatheter mitral valve repair for those with significant MR. Thus far, evidence-based 
medical therapy with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers have been demonstrated to be cost-effective in most cases, with 
an ICER between $1000-$10,000 per QALY, and in some settings cost-saving(64). Device 
therapy with defibrillators and CRT has an increased cost of $43,000 to $60,000 per 
QALY(44, 65) but are thought to be cost-effective given the associated reductions in 
hospitalizations and mortality.  However, consideration must be given to the maintenance 
costs of such devices, particularly in the setting of primary prevention. Mechanical circulatory 
support with left ventricular assist devices have been increasingly considered for patients as a 
bridge to transplant or as destination therapy but are extremely costly, with an ICER of over 
$300,000 per QALY for the Heart Mate II device(66). Treatment with the MitraClip device 
has been shown to improve QoL in heart failure patients following optimal medical therapy 
and in CRT non-responders(29, 67). Nevertheless, cost-effectiveness in this population has yet 
to be evaluated in a randomized trial. Given the prognosis of patients with advanced heart 
failure and secondary MR, the question of whether the addition of MitraClip to standard 
therapy can provide meaningful health benefits to the population at an acceptable cost is 
particularly germane. 
 Our study has evaluated the cost-effectiveness of MitraClip in an actual cohort of 
patients with heart failure and FMR and compared these results to a cohort of patients 
managed medically.  In this setting, MitraClip has been shown to be a cost-effective therapy 
with an impact on both mortality and hospitalizations for recurrent heart failure.  This study 
provides valuable information to clinicians and hospital administrators responsible for care of 
patients in whom transcatheter mitral valve repair with the MitraClip may be considered.  
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Study Limitations  
The key limitations of this study are the small sample size; differences in functional 
class at baseline in both groups and the limited follow up data available requiring certain 
assumptions for the purposes of the economic model.  Although the sample size was limited 
by the recent availability and restricted access to the MitraClip in Canada, we feel that the 
patients included are representative of the larger target population.  The medical management 
cohort was comprised of patients followed in the Heart Failure Clinic in the two years prior to 
availability of the MitraClip. Patients in this cohort received GDMT for heart failure. The 
patients in this group did have a lower ejection fraction than the MitraClip cohort despite the 
matching process, and this may be related to their higher mortality at follow up. The modest 
number of patients with cardiac resynchronization therapy may reflect the better functional 
class in this group.  Given the significant differences in baseline functional class between the 
MitraClip and medical management cohorts, NYHA class was not included in the propensity 
matching. The medical cohort was less symptomatic with the majority of patients reporting 
NYHA class II symptoms, compared to the predominantly class IV symptoms in the MitraClip 
group.  Although this is surprising this is not an isolated finding.  A review of over 1200 
patients by Rossi et al with FMR demonstrated that up to 40% of patients with severe MR 
were actually NYHA Class II or II but despite this fact, the overall mortality at five years in 
those with severe MR was almost 70%(6).  In order to further understand the impact of 
differences in NYHA Class, we made the assumption that all patients treated with MitraClip 
and medical therapy advanced by one NYHA class per year in follow up. A sensitivity 
analysis was then performed to assess this and found no significant difference in the ICER 
whether the patients remained in their NYHA Class at model onset or progressed over time. In 
our study, the impact of the MitraClip on improved survival, reduced hospitalization costs, ER 
costs and mitral valve surgery costs may have been underestimated given that higher NYHA 
functional classes are associated with increased risk of hospitalization and mortality in heart 
failure patients but this will require validation in larger randomized trials(68).  
The economic study can be criticized for being based on observational data rather than 
randomized controlled trial data. However, such data is currently unavailable.  In addition, this 
analysis is based on the outcomes of real-world clinical patients as opposed to carefully 
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screened and selected trial subjects. The study was limited by the need to extrapolate survival 
for both cohorts beyond the follow up available, resulting in a relatively wide confidence 
interval for the hazard ratio of MitraClip vs. medical therapy. This is reflected by the spread of 
the data in the probabilistic sensitivity analyses (Figure 9). However, the mortality rates 
estimated by the model were consistent with mortality rates observed in existing registries of 
patients with CHF and FMR and managed medically or treated with the MitraClip (6, 10, 31). 
Despite these limitations, the findings of this analysis are in keeping with the aforementioned 
UK cost-effectiveness analysis of MitraClip in high-risk patients.  
External validity 
The EVEREST High Risk Registry demonstrated clinical effectiveness in a high-risk 
surgical population with a mean ejection fraction of 54% and 3-4+ MR with a procedural 
success of 96%, 30-day mortality of 7.7% and a 12-month survival of 76%(58).  In 
comparison to the concurrent comparator group treated medically, an improvement in survival 
became evident at 6 months and continued out to 12 months.  Our matched analysis 
demonstrates similar survival at ten months at which point the curves began separating with a 
mortality benefit that was statistically significant for those treated with MitraClip. 
Published European experience in patients with predominantly FMR and lower 
ejection fractions has been equally encouraging. Recently, data from the Pilot European 
Sentinel Registry showed similar success and mortality rates to ACCESS-EU with higher 
incidence of re-hospitalization for heart failure and NYHA class III-IV in patients with 
FMR(31). In comparison to the two groups described above, the patient cohort at the MHI was 
higher risk, with more advanced left ventricular dysfunction (mean EF 38%) and mostly FMR.  
Despite these differences, treatment with MitraClip in our cohort demonstrated comparable 
success rates and 12-month survival to registry data, as shown in Table 7. 
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Table 7. Comparison of Outcomes in MitraClip Cohort with published Registry Data 
	  
Outcome	   MHI	  Experience	  	  
(n=50)	  
ACCESS-­‐EU	  	  
(n=567)	  
Sentinel	  Registry	  
(n=628)	  	   30	  days	   12	  months	   30	  days	   12	  months	   30	  days	   12	  months	  Procedural	  Success	   96%	  (48)	   NA	   91.2%	   NA	   95.4%	   NA	  All-­‐cause	  mortality	   8%	  (4)	   18%	  (9)	   3.4%	  (19)	   17%	  (98)	   2.9%	  (18)	   15.3%	  (84)	  Mitral	  Valve	  Surgery	   4%	  (2)	   6%	  (3)	   0.04%	  (2)	   6%	  (36)	   NA	   NA	  
  
Conclusion 
 Heart failure is increasing in prevalence and incidence and the outcome associated 
with it is poor. As this global problem increases so does the economic burden of the 
disease(69).  MR is common in the heart failure population, with 25% of patients in one series 
having severe MR(6).  In patients with left ventricular dysfunction, the presence of severe MR 
has been associated with an all-cause mortality of 45% at four years despite optimal medical 
therapy(20). Observational studies to date, have demonstrated that transcatheter therapy using 
the MitraClip is safe and effective at reducing MR.   
We performed a cost utility analysis of the MitraClip in patients with heart failure and 
significant MR to evaluate the economic impact of such technology from the perspective of 
the Canadian health care system.  In comparison to patients treated medically, those treated 
with the MitraClip had lower rates of hospitalization for heart failure and reduced mortality at 
follow up. This resulted in therapy with the MitraClip being cost-effective in the majority of 
patients with an incremental cost-effectiveness ratio of $32,300.00.  Given the results of this 
analysis, it would appear that in the Canadian healthcare system, treatment of MR in heart 
failure patients with the MitraClip is cost-effective.
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